IMMIX BIOPHARMA, INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
IMMIX BIOPHARMA, INC. (IMMX) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $11.85 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$12.81K.
- IMMIX BIOPHARMA, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was -$8.00K.
- IMMIX BIOPHARMA, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$10.37K.
- IMMIX BIOPHARMA, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$562.00.
- IMMIX BIOPHARMA, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $3.84K.
- IMMIX BIOPHARMA, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$3.62K, a 110.95% decline from fiscal 2023.
- IMMIX BIOPHARMA, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $33.09K.
- IMMIX BIOPHARMA, INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$31.52K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.85K 10-Q · filed 2026-08-07 | |||
| 2026-03-31 | -$12.81K 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $3.84K 10-K/A · filed 2026-03-27 | |||
| 2025-09-30 | $15.59K 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $36.14K 10-Q · filed 2026-08-07 | |||
| 2025-03-31 | -$8.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$3.62K 10-K/A · filed 2026-03-27 | |||
| 2024-09-30 | $21.51K 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | -$1.46K 10-Q · filed 2025-08-08 | |||
| 2024-03-31 | -$10.37K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $33.09K 10-K · filed 2025-03-25 | |||
| 2023-09-30 | $1.80K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | $13.57K 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | -$562.00 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$31.52K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | -$31.37K 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$8.03K 10-Q · filed 2023-08-11 | |||
| 2022-03-31 | -$2.72K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$5.43K 10-K · filed 2023-03-27 | |||
| 2021-09-30 | -$6.05K 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | -$2.56K 10-Q · filed 2022-08-12 | |||
| 2021-03-31 | -$8.04K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |